-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 2, Boehringer Ingelheim and Zealand Pharma jointly announced that the FDA has granted GLP-1/glucagon receptor (GCCR) dual agonist BI 456906 fast track designation for adult non-alcoholic steatohepatitis ( NASH).
BI 456906 is derived from the natural intestinal hormone oxyntomodulin, which can activate GLP-1 and glucagon receptors that are essential for controlling metabolic functions.
Currently, BI 456906 is conducting a randomized, double-blind, placebo-controlled Phase II clinical study (NCT04771273) to evaluate the efficacy of the drug in adult patients with NASH and liver fibrosis (F2/F3).
In China, Boehringer Ingelheim submitted a clinical application as early as December 22, 2020, and has launched an international multi-center phase 2 clinical trial for obese patients.
Domestic progress of BI 456906 project
From the Insight database (http://db.
Non-alcoholic steatohepatitis (NASH) is one of the main causes of liver fibrosis and cirrhosis.
Note: The original text has been deleted